JEVTANA 60 mg concentrate and solvent for solution for infusion.

DRUG3 trials

Sponsors

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Unicancer, Rigshospitalet

Conditions

Patients with localized prostate cancer and high-risk features of relapse.metastatic castration-resistant prostate cancermetastatic castration-resistant prostate cancer (mCRPC)

Phase 2

A randomized phase II trial of docetaxel or cabazitaxel with or without darolutamide in men with metastatic castration-resistant prostate cancer.

Not yet recruitingCTIS2024-516939-28-00

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)metastatic castration-resistant prostate cancer

Target: 245Updated: 2025-12-03

Ebastine in combination with docetaxel or cabazitaxel as a treatment for metastatic castration-resistant prostate cancer

RecruitingCTIS2024-518035-11-01

Rigshospitaletmetastatic castration-resistant prostate cancer (mCRPC)

Start: 2024-06-02Target: 30Updated: 2025-08-22

Phase 3

PEACE2 : A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse

Active, not recruitingCTIS2024-517622-25-00

UnicancerPatients with localized prostate cancer and high-risk features of relapse.

Start: 2013-12-06Target: 760Updated: 2024-12-13